OSWALDO CASTRO, M.D.; LEONARD R. FARBER, M.D.; LIONEL P. CLYNE
Supported in part by training grant HE 05316-11 and research grant HE 09057-08, U.S. Public Health Service, Washington, D.C., a research grant from the American Heart Association, New York, N.Y., and Veterans Administration Research funds, Veterans Administration Hospital, West Haven, Conn.
▸Requests for reprints should be addressed to Oswaldo Castro, M.D., Department of Internal Medicine, Yale University School of Medicine, 333 Cedar St., New Haven, Conn. 06510.
CASTRO O, FARBER LR, CLYNE LP. Circulating Anticoagulants Against Factors IX and XI in Systemic Lupus Erythematosus. Ann Intern Med. 1972;77:543-548. doi: 10.7326/0003-4819-77-4-543
Download citation file:
Published: Ann Intern Med. 1972;77(4):543-548.
In four patients with systemic lupus erythematosus and unusual circulating anticoagulants the partial thromboplastin time of normal plasma was prolonged by the patient's plasma, but the prothrombin time was normal. Low plasma levels of factor IX in one case and of factor XI in two cases were the only coagulation abnormalities, suggesting that the anticoagulant was directed against these factors. In the fourth patient, assay values of factors V, VIII, IX, and X were not low enough to explain the prolonged partial thromboplastin time. Adequate contact product was found, but the patient's plasma had anticoagulant activity against her own and normal contact product. This interfered with assays of factors XI and XII; we believe that in this patient the anticoagulant was directed against activated factor XI. In two cases there was significant bleeding. Treatment with prednisone and immunosuppressive agents resulted in disappearance of the clotting abnormalities.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Rheumatology, Lupus Erythematosus.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only